These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 31456347

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Mechanisms underlying acquired platinum resistance in high grade serous ovarian cancer - a mini review.
    Binju M, Padilla MA, Singomat T, Kaur P, Suryo Rahmanto Y, Cohen PA, Yu Y.
    Biochim Biophys Acta Gen Subj; 2019 Feb; 1863(2):371-378. PubMed ID: 30423357
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Cellular pharmacology of cis and trans pairs of platinum complexes in cisplatin-sensitive and -resistant human ovarian carcinoma cells.
    O'Neill CF, Hunakova L, Kelland LR.
    Chem Biol Interact; 1999 Nov 15; 123(1):11-29. PubMed ID: 10597899
    [Abstract] [Full Text] [Related]

  • 6. Nanoparticle-based drug delivery systems with platinum drugs for overcoming cancer drug resistance.
    Xie P, Wang Y, Wei D, Zhang L, Zhang B, Xiao H, Song H, Mao X.
    J Mater Chem B; 2021 Jul 07; 9(26):5173-5194. PubMed ID: 34116565
    [Abstract] [Full Text] [Related]

  • 7. Mechanism of action of an orally administered platinum complex [ammine bis butyrato cyclohexylamine dichloroplatinum (IV) (JM221)] in intrinsically cisplatin-resistant human ovarian carcinoma in vitro.
    McKeage MJ, Abel G, Kelland LR, Harrap KR.
    Br J Cancer; 1994 Jan 07; 69(1):1-7. PubMed ID: 8286188
    [Abstract] [Full Text] [Related]

  • 8. New markers for human ovarian cancer that link platinum resistance to the cancer stem cell phenotype and define new therapeutic combinations and diagnostic tools.
    Muñoz-Galván S, Felipe-Abrio B, García-Carrasco M, Domínguez-Piñol J, Suarez-Martinez E, Verdugo-Sivianes EM, Espinosa-Sánchez A, Navas LE, Otero-Albiol D, Marin JJ, Jiménez-García MP, García-Heredia JM, Quiroga AG, Estevez-Garcia P, Carnero A.
    J Exp Clin Cancer Res; 2019 Jun 03; 38(1):234. PubMed ID: 31159852
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
    Alkema NG, Tomar T, van der Zee AG, Everts M, Meersma GJ, Hollema H, de Jong S, van Vugt MA, Wisman GB.
    Gynecol Oncol; 2014 Jun 03; 133(3):591-8. PubMed ID: 24657486
    [Abstract] [Full Text] [Related]

  • 15. Mechanistic Nanotherapeutic Approach Based on siRNA-Mediated DJ-1 Protein Suppression for Platinum-Resistant Ovarian Cancer.
    Schumann C, Chan S, Khalimonchuk O, Khal S, Moskal V, Shah V, Alani AW, Taratula O, Taratula O.
    Mol Pharm; 2016 Jun 06; 13(6):2070-83. PubMed ID: 27170529
    [Abstract] [Full Text] [Related]

  • 16. Costunolide induces apoptosis in platinum-resistant human ovarian cancer cells by generating reactive oxygen species.
    Yang YI, Kim JH, Lee KT, Choi JH.
    Gynecol Oncol; 2011 Dec 06; 123(3):588-96. PubMed ID: 21945308
    [Abstract] [Full Text] [Related]

  • 17. DNA-binding properties of novel cis- and trans platinum-based anticancer agents in 2 human ovarian carcinoma cell lines.
    Mellish KJ, Barnard CF, Murrer BA, Kelland LR.
    Int J Cancer; 1995 Sep 15; 62(6):717-23. PubMed ID: 7558420
    [Abstract] [Full Text] [Related]

  • 18. Synthesis of a monofunctional platinum compound and its activity alone and in combination with phytochemicals in ovarian tumor models.
    Arzuman L, Beale P, Yu JQ, Proschogo N, Huq F.
    Anticancer Res; 2014 Dec 15; 34(12):7077-90. PubMed ID: 25503135
    [Abstract] [Full Text] [Related]

  • 19. Preclinical activity of lobaplatin as a single agent and in combination with taxanes for ovarian carcinoma cells.
    Sun X, Lou LG, Sui DH, Wu XH.
    Asian Pac J Cancer Prev; 2014 Dec 15; 15(22):9939-43. PubMed ID: 25520132
    [Abstract] [Full Text] [Related]

  • 20. Development of resistance to a trinuclear platinum complex in ovarian carcinoma cells.
    Perego P, Gatti L, Righetti SC, Beretta GL, Carenini N, Corna E, Dal Bo L, Tinelli S, Colangelo D, Leone R, Apostoli P, Lombardi L, Beggiolin G, Piazzoni L, Zunino F.
    Int J Cancer; 2003 Jul 10; 105(5):617-24. PubMed ID: 12740909
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.